Programs

Pipeline

discovery and research Lead Optimization IND-Enabling Phase 1 azp-3601 azp-3404

PROGRAMS

AZP-3601: Hypoparathyroidism

AZP-3601 is a peptide analog of parathyroid hormone (PTH) that targets a specific configuration of the PTH1 receptor to safely produce sustained levels of calcium in the blood and thereby control the symptoms of hypoparathyroidism.1

AZP-3601 has been designed to prevent chronic kidney disease by limiting the amount of calcium eliminated in the urine, and to preserve bone integrity, an important benefit since a large proportion of patients with hypoparathyroidism are middle-aged women often at an increased risk of developing osteoporosis.

AZP-3601 has already demonstrated an optimal pharmacological profile in several preclinical studies.2,3 We have successfully completed pre-investigational new drug activities and a Phase 1 clinical study has been initiated in September 2020.

AZP-3404

AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2), and to utilize multiple, well-established pathways to restore the body’s regulation of fat and glucose metabolism.

IGFBP2 is a protein that carries out the actions of leptin, a hormone that regulates fat and glucose metabolism. The ability of IGFBP2 to do this resides in a small peptide sequence within its structure. AZP-3404 is a stabilized peptide analog of this sequence and is the first drug candidate to reproduce and utilize the unique biology of IGFBP2.4,5,6

We are currently conducting pre-investigation new drug activities and exploring target indications for AZP-3404.

insulin like growth factor binding protein 2
Scroll to Top